What is the scope of this Clinical Practice Guideline?
The scope of this Clinical Practice Guideline includes populations that are at risk for dyslipidemia and cardiovascular disease, as well as those who have already been diagnosed with dyslipidemia and are receiving treatment. The populations excluded are those with conditions that may affect the outcomes of the guideline, such as pregnant women, those with end-stage renal disease, or those with certain genetic mutations. It also does not provide guidance for the management of lipoprotein(a) or genetic testing. 